Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 4
2007 1
2008 1
2009 2
2010 3
2012 3
2013 1
2014 1
2015 1
2017 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for C. ragonesi
Your search for C. Ragonezi retrieved no results
Estimation and characterisation of budesonide tablets impurities.
Ferraboschi P, Bertacche V, Maccone I, Pini E, Ragonesi L, Venturini A, Stradi R. Ferraboschi P, et al. J Pharm Biomed Anal. 2008 Jul 15;47(3):636-40. doi: 10.1016/j.jpba.2008.01.050. Epub 2008 Feb 16. J Pharm Biomed Anal. 2008. PMID: 18367362
In a sample of budesonide tablets, kept for 3 years at 25 degrees C and 60% RH unknown impurities, not reported in European Pharmacopoiea, were present. ...
In a sample of budesonide tablets, kept for 3 years at 25 degrees C and 60% RH unknown impurities, not reported in European Pharmacop …
Exenatide versus glibenclamide in patients with diabetes.
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF. Derosa G, et al. Diabetes Technol Ther. 2010 Mar;12(3):233-40. doi: 10.1089/dia.2009.0141. Diabetes Technol Ther. 2010. PMID: 20151774 Clinical Trial.
We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA(1c)), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance (HOMA-IR) index, homeostasis model assessment beta-cell f …
We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA(1c)), fasting plasma glucose (FPG), postprandial plasma glucose (P …
Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF. Derosa G, et al. J Clin Pharm Ther. 2009 Jun;34(3):267-76. doi: 10.1111/j.1365-2710.2008.01004.x. J Clin Pharm Ther. 2009. PMID: 19650249 Clinical Trial.

RESULTS AND DISCUSSION: All 1170 Caucasian patients affected by polygenic hypercholesterolemia obtained a significant reduction in LDL-C during the observation period (P < 0*05), while those with combined hyperlipidemia also showed a reduction in TG plasma level (P <

…
RESULTS AND DISCUSSION: All 1170 Caucasian patients affected by polygenic hypercholesterolemia obtained a significant reduction in LDL-C …
A quality improvement program to reduce surgical site infections after cardiac surgery: A 10-year cohort study.
Conoscenti E, Enea G, Deschepper M, In 't Veld DH, Campanella M, Raffa G, Ragonesi B, Mularoni A, Mattina A, Blot S. Conoscenti E, et al. Intensive Crit Care Nurs. 2024 Dec 19;87:103926. doi: 10.1016/j.iccn.2024.103926. Online ahead of print. Intensive Crit Care Nurs. 2024. PMID: 39705757 Free article.
OBJECTIVES: To assess trends in surgical site infection (SSI) incidence in cardiosurgery following a quality improvement initiative in infection prevention and control (IP&C). METHODS: This is a historical cohort study encompassing a 10-year surveillance period (2014-2 …
OBJECTIVES: To assess trends in surgical site infection (SSI) incidence in cardiosurgery following a quality improvement initiative in infec …
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, Maffioli P. Derosa G, et al. Expert Opin Pharmacother. 2012 Dec;13(18):2581-91. doi: 10.1517/14656566.2012.734499. Epub 2012 Nov 3. Expert Opin Pharmacother. 2012. PMID: 23121473 Clinical Trial.
MAIN OUTCOME MEASURES: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment beta-cell function index (HOMA-beta), fasting pl …
MAIN OUTCOME MEASURES: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), ho …
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF. Derosa G, et al. J Clin Pharm Ther. 2006 Aug;31(4):375-83. doi: 10.1111/j.1365-2710.2006.00756.x. J Clin Pharm Ther. 2006. PMID: 16882108 Clinical Trial.
We assessed body mass index (BMI), glycaemic control [glycosylated haemoglobin (HbA(1c)), fasting and postprandial plasma glucose and insulin levels (FPG, PPG, FPI, and PPI respectively), homeostasis model assessment (HOMA) index], lipid profile [total cholesterol (TC), low-densi …
We assessed body mass index (BMI), glycaemic control [glycosylated haemoglobin (HbA(1c)), fasting and postprandial plasma glucose and insuli …
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, Maffioli P. Derosa G, et al. Pharmacol Res. 2013 Jul;73:20-6. doi: 10.1016/j.phrs.2013.04.005. Epub 2013 Apr 26. Pharmacol Res. 2013. Retraction in: Pharmacol Res. 2017 Jul;121:255. doi: 10.1016/j.phrs.2017.05.027 PMID: 23624419 Retracted. Clinical Trial.
Body mass index (BMI), glycemic control, fasting plasma insulin (FPI), HOMA-IR, HOMA-beta, fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, vaspin, visfatin, and omentin-1 were evaluated. Before, and after 12 mo …
Body mass index (BMI), glycemic control, fasting plasma insulin (FPI), HOMA-IR, HOMA-beta, fasting plasma proinsulin (FPPr), proinsulin/fast …
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
Derosa G, Ragonesi PD, Fogari E, Cicero AF, Bianchi L, Bonaventura A, Romano D, Maffioli P. Derosa G, et al. Fundam Clin Pharmacol. 2014 Apr;28(2):221-9. doi: 10.1111/fcp.12001. Epub 2012 Oct 8. Fundam Clin Pharmacol. 2014. PMID: 23039403 Clinical Trial.
We evaluated at the baseline and after 6, 12, 18, and 24 months the following parameters: body mass index, glycated hemoglobin (HbA1c ), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance …
We evaluated at the baseline and after 6, 12, 18, and 24 months the following parameters: body mass index, glycated hemoglobin (HbA1c ), fas …
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P. Derosa G, et al. Diabetes Technol Ther. 2012 Jun;14(6):475-84. doi: 10.1089/dia.2011.0278. Epub 2012 Apr 18. Diabetes Technol Ther. 2012. PMID: 22512264 Clinical Trial.
We evaluated at 3, 6, 9, and 12 months: body mass index, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment beta-cell function index (HOMA-beta), fasting plasma proinsulin, proinsulin/fasting pla …
We evaluated at 3, 6, 9, and 12 months: body mass index, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resi …
19 results